Proliferating Fraction During Neoadjuvant Chemotherapy of Primary Breast Cancer in Relation to Objective Local Response and Relapse-free Survival
In women with inoperable primary breast cancer or large T2 tumors, preoperative chemotherapy may induce tumor shrinkage, facilitate surgery and possibly improve survival 1. However, at present there are no reliable tumor cell parameters to predict which patients will benefit from preoperative chemot...
Gespeichert in:
| Veröffentlicht in: | Acta oncologica 1999, Vol.38 (5), p.597-601 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 601 |
|---|---|
| container_issue | 5 |
| container_start_page | 597 |
| container_title | Acta oncologica |
| container_volume | 38 |
| creator | BILLGREN, A.-M RUTQVIST, L. E TANI, E WILKING, N FORNANDER, T SKOOG, L |
| description | In women with inoperable primary breast cancer or large T2 tumors, preoperative chemotherapy may induce tumor shrinkage, facilitate surgery and possibly improve survival 1. However, at present there are no reliable tumor cell parameters to predict which patients will benefit from preoperative chemotherapy. The aims of this study were to analyze the utility of tumor cell proliferation as assessed by Ki-67 staining in fine-needle aspirates from primary breast carcinomas to predict initial response to neoadjuvant chemotherapy as well as recurrence-free survival. The study comprised 51 women with primary breast cancer who received 3-4 courses of CEF (cyclophosphamide, epirubicin, 5-fluorouracil) as neoadjuvant chemotherapy. Tumor cells were procured through fine-needle aspiration biopsy prior to treatment. A second biopsy was performed before the second course of therapy in 33 women. Twenty-nine women (56%) experienced an objective local response after neoadjuvant treatment. During a median follow-up period of 39 months, 21 women (41%) developed disease recurrence. A decrease of more than 25% in proliferating fraction after the first course of chemotherapy correlated significantly with a decreased risk of disease recurrence (p=0.033) but showed no significant correlation with local objective response. A multivariate analysis revealed that the decrease in proliferating fraction significantly (p |
| doi_str_mv | 10.1080/028418699431186 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_604748</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10427948</sourcerecordid><originalsourceid>FETCH-LOGICAL-c546t-ad87d20523e80de0c10cb9097cee0ba34d3e1aba9b8a6da946d8a40a76febb883</originalsourceid><addsrcrecordid>eNp1kU9v1DAQxS0EokvhzA35wDXUTryOfYQtBaRVW_FH6i2a2BPWS9aO7GRRP0a_Md5m1SIkTmPP-82T_YaQ15y940yxM1YqwZXUWlQ81ydkweWSF2Upb56SxUEtcvvmhLxIacsYK6t6-ZyccCbKWgu1IHfXMfSuwwij8z_pRQQzuuDp-RQP90sMYLfTHvxIVxvchXGT0eGWho5eR7eDeEs_RISUZfAGI3WefsUe7k3GQK_aLWbHPdJ1MNBnLQ3BJ6Tg7T04JCy6iEi_TXHv9tC_JM866BO-OtZT8uPi4_fV52J99enL6v26MEshxwKsqm3JlmWFillkhjPTaqZrg8haqIStkEMLulUgLWghrQLBoJYdtq1S1SkpZt_0G4epbYb5O00A1xxbv_IJG8lELQ782cybGFKK2D1McNYcltH8s4w88WaeyF47tH_xc_oZeHsEIOVwupgjdOmRU7WSUmdMz5jzXYg72CD048ZAxGYbpuhzSv99wx_GV6er</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Proliferating Fraction During Neoadjuvant Chemotherapy of Primary Breast Cancer in Relation to Objective Local Response and Relapse-free Survival</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Taylor & Francis Journals Complete</source><creator>BILLGREN, A.-M ; RUTQVIST, L. E ; TANI, E ; WILKING, N ; FORNANDER, T ; SKOOG, L</creator><creatorcontrib>BILLGREN, A.-M ; RUTQVIST, L. E ; TANI, E ; WILKING, N ; FORNANDER, T ; SKOOG, L</creatorcontrib><description>In women with inoperable primary breast cancer or large T2 tumors, preoperative chemotherapy may induce tumor shrinkage, facilitate surgery and possibly improve survival 1. However, at present there are no reliable tumor cell parameters to predict which patients will benefit from preoperative chemotherapy. The aims of this study were to analyze the utility of tumor cell proliferation as assessed by Ki-67 staining in fine-needle aspirates from primary breast carcinomas to predict initial response to neoadjuvant chemotherapy as well as recurrence-free survival. The study comprised 51 women with primary breast cancer who received 3-4 courses of CEF (cyclophosphamide, epirubicin, 5-fluorouracil) as neoadjuvant chemotherapy. Tumor cells were procured through fine-needle aspiration biopsy prior to treatment. A second biopsy was performed before the second course of therapy in 33 women. Twenty-nine women (56%) experienced an objective local response after neoadjuvant treatment. During a median follow-up period of 39 months, 21 women (41%) developed disease recurrence. A decrease of more than 25% in proliferating fraction after the first course of chemotherapy correlated significantly with a decreased risk of disease recurrence (p=0.033) but showed no significant correlation with local objective response. A multivariate analysis revealed that the decrease in proliferating fraction significantly (p<0.05) added prognostic information to that of involved lymph nodes. These results suggest that changes in proliferating fraction as assessed by Ki-67 staining in fine-needle aspirates during preoperative chemotherapy may be of value in selecting postoperative adjuvant systemic treatment.</description><identifier>ISSN: 0284-186X</identifier><identifier>EISSN: 1651-226X</identifier><identifier>DOI: 10.1080/028418699431186</identifier><identifier>PMID: 10427948</identifier><identifier>CODEN: ACTOEL</identifier><language>eng</language><publisher>Basingstoke: Informa UK Ltd</publisher><subject>Adult ; Aged ; Antineoplastic agents ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Breast Neoplasms - drug therapy ; Breast Neoplasms - pathology ; Cell Division ; Chemotherapy ; Cyclophosphamide - administration & dosage ; Disease-Free Survival ; Epirubicin - administration & dosage ; Female ; Fluorouracil - administration & dosage ; Humans ; Ki-67 Antigen - analysis ; Medical sciences ; Middle Aged ; Neoadjuvant Therapy ; Neoplasm Recurrence, Local ; Patient Selection ; Pharmacology. Drug treatments ; Predictive Value of Tests ; Prognosis ; Treatment Outcome</subject><ispartof>Acta oncologica, 1999, Vol.38 (5), p.597-601</ispartof><rights>1999 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 1999</rights><rights>1999 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c546t-ad87d20523e80de0c10cb9097cee0ba34d3e1aba9b8a6da946d8a40a76febb883</citedby><cites>FETCH-LOGICAL-c546t-ad87d20523e80de0c10cb9097cee0ba34d3e1aba9b8a6da946d8a40a76febb883</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1080/028418699431186$$EPDF$$P50$$Ginformahealthcare$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1080/028418699431186$$EHTML$$P50$$Ginformahealthcare$$H</linktohtml><link.rule.ids>230,314,776,780,881,4010,27900,27901,27902,61194,61375</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1878669$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10427948$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:1934799$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>BILLGREN, A.-M</creatorcontrib><creatorcontrib>RUTQVIST, L. E</creatorcontrib><creatorcontrib>TANI, E</creatorcontrib><creatorcontrib>WILKING, N</creatorcontrib><creatorcontrib>FORNANDER, T</creatorcontrib><creatorcontrib>SKOOG, L</creatorcontrib><title>Proliferating Fraction During Neoadjuvant Chemotherapy of Primary Breast Cancer in Relation to Objective Local Response and Relapse-free Survival</title><title>Acta oncologica</title><addtitle>Acta Oncol</addtitle><description>In women with inoperable primary breast cancer or large T2 tumors, preoperative chemotherapy may induce tumor shrinkage, facilitate surgery and possibly improve survival 1. However, at present there are no reliable tumor cell parameters to predict which patients will benefit from preoperative chemotherapy. The aims of this study were to analyze the utility of tumor cell proliferation as assessed by Ki-67 staining in fine-needle aspirates from primary breast carcinomas to predict initial response to neoadjuvant chemotherapy as well as recurrence-free survival. The study comprised 51 women with primary breast cancer who received 3-4 courses of CEF (cyclophosphamide, epirubicin, 5-fluorouracil) as neoadjuvant chemotherapy. Tumor cells were procured through fine-needle aspiration biopsy prior to treatment. A second biopsy was performed before the second course of therapy in 33 women. Twenty-nine women (56%) experienced an objective local response after neoadjuvant treatment. During a median follow-up period of 39 months, 21 women (41%) developed disease recurrence. A decrease of more than 25% in proliferating fraction after the first course of chemotherapy correlated significantly with a decreased risk of disease recurrence (p=0.033) but showed no significant correlation with local objective response. A multivariate analysis revealed that the decrease in proliferating fraction significantly (p<0.05) added prognostic information to that of involved lymph nodes. These results suggest that changes in proliferating fraction as assessed by Ki-67 staining in fine-needle aspirates during preoperative chemotherapy may be of value in selecting postoperative adjuvant systemic treatment.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - pathology</subject><subject>Cell Division</subject><subject>Chemotherapy</subject><subject>Cyclophosphamide - administration & dosage</subject><subject>Disease-Free Survival</subject><subject>Epirubicin - administration & dosage</subject><subject>Female</subject><subject>Fluorouracil - administration & dosage</subject><subject>Humans</subject><subject>Ki-67 Antigen - analysis</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neoadjuvant Therapy</subject><subject>Neoplasm Recurrence, Local</subject><subject>Patient Selection</subject><subject>Pharmacology. Drug treatments</subject><subject>Predictive Value of Tests</subject><subject>Prognosis</subject><subject>Treatment Outcome</subject><issn>0284-186X</issn><issn>1651-226X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kU9v1DAQxS0EokvhzA35wDXUTryOfYQtBaRVW_FH6i2a2BPWS9aO7GRRP0a_Md5m1SIkTmPP-82T_YaQ15y940yxM1YqwZXUWlQ81ydkweWSF2Upb56SxUEtcvvmhLxIacsYK6t6-ZyccCbKWgu1IHfXMfSuwwij8z_pRQQzuuDp-RQP90sMYLfTHvxIVxvchXGT0eGWho5eR7eDeEs_RISUZfAGI3WefsUe7k3GQK_aLWbHPdJ1MNBnLQ3BJ6Tg7T04JCy6iEi_TXHv9tC_JM866BO-OtZT8uPi4_fV52J99enL6v26MEshxwKsqm3JlmWFillkhjPTaqZrg8haqIStkEMLulUgLWghrQLBoJYdtq1S1SkpZt_0G4epbYb5O00A1xxbv_IJG8lELQ782cybGFKK2D1McNYcltH8s4w88WaeyF47tH_xc_oZeHsEIOVwupgjdOmRU7WSUmdMz5jzXYg72CD048ZAxGYbpuhzSv99wx_GV6er</recordid><startdate>1999</startdate><enddate>1999</enddate><creator>BILLGREN, A.-M</creator><creator>RUTQVIST, L. E</creator><creator>TANI, E</creator><creator>WILKING, N</creator><creator>FORNANDER, T</creator><creator>SKOOG, L</creator><general>Informa UK Ltd</general><general>Taylor & Francis</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ADTPV</scope><scope>AOWAS</scope></search><sort><creationdate>1999</creationdate><title>Proliferating Fraction During Neoadjuvant Chemotherapy of Primary Breast Cancer in Relation to Objective Local Response and Relapse-free Survival</title><author>BILLGREN, A.-M ; RUTQVIST, L. E ; TANI, E ; WILKING, N ; FORNANDER, T ; SKOOG, L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c546t-ad87d20523e80de0c10cb9097cee0ba34d3e1aba9b8a6da946d8a40a76febb883</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - pathology</topic><topic>Cell Division</topic><topic>Chemotherapy</topic><topic>Cyclophosphamide - administration & dosage</topic><topic>Disease-Free Survival</topic><topic>Epirubicin - administration & dosage</topic><topic>Female</topic><topic>Fluorouracil - administration & dosage</topic><topic>Humans</topic><topic>Ki-67 Antigen - analysis</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neoadjuvant Therapy</topic><topic>Neoplasm Recurrence, Local</topic><topic>Patient Selection</topic><topic>Pharmacology. Drug treatments</topic><topic>Predictive Value of Tests</topic><topic>Prognosis</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>BILLGREN, A.-M</creatorcontrib><creatorcontrib>RUTQVIST, L. E</creatorcontrib><creatorcontrib>TANI, E</creatorcontrib><creatorcontrib>WILKING, N</creatorcontrib><creatorcontrib>FORNANDER, T</creatorcontrib><creatorcontrib>SKOOG, L</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>SwePub</collection><collection>SwePub Articles</collection><jtitle>Acta oncologica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>BILLGREN, A.-M</au><au>RUTQVIST, L. E</au><au>TANI, E</au><au>WILKING, N</au><au>FORNANDER, T</au><au>SKOOG, L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Proliferating Fraction During Neoadjuvant Chemotherapy of Primary Breast Cancer in Relation to Objective Local Response and Relapse-free Survival</atitle><jtitle>Acta oncologica</jtitle><addtitle>Acta Oncol</addtitle><date>1999</date><risdate>1999</risdate><volume>38</volume><issue>5</issue><spage>597</spage><epage>601</epage><pages>597-601</pages><issn>0284-186X</issn><eissn>1651-226X</eissn><coden>ACTOEL</coden><abstract>In women with inoperable primary breast cancer or large T2 tumors, preoperative chemotherapy may induce tumor shrinkage, facilitate surgery and possibly improve survival 1. However, at present there are no reliable tumor cell parameters to predict which patients will benefit from preoperative chemotherapy. The aims of this study were to analyze the utility of tumor cell proliferation as assessed by Ki-67 staining in fine-needle aspirates from primary breast carcinomas to predict initial response to neoadjuvant chemotherapy as well as recurrence-free survival. The study comprised 51 women with primary breast cancer who received 3-4 courses of CEF (cyclophosphamide, epirubicin, 5-fluorouracil) as neoadjuvant chemotherapy. Tumor cells were procured through fine-needle aspiration biopsy prior to treatment. A second biopsy was performed before the second course of therapy in 33 women. Twenty-nine women (56%) experienced an objective local response after neoadjuvant treatment. During a median follow-up period of 39 months, 21 women (41%) developed disease recurrence. A decrease of more than 25% in proliferating fraction after the first course of chemotherapy correlated significantly with a decreased risk of disease recurrence (p=0.033) but showed no significant correlation with local objective response. A multivariate analysis revealed that the decrease in proliferating fraction significantly (p<0.05) added prognostic information to that of involved lymph nodes. These results suggest that changes in proliferating fraction as assessed by Ki-67 staining in fine-needle aspirates during preoperative chemotherapy may be of value in selecting postoperative adjuvant systemic treatment.</abstract><cop>Basingstoke</cop><pub>Informa UK Ltd</pub><pmid>10427948</pmid><doi>10.1080/028418699431186</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0284-186X |
| ispartof | Acta oncologica, 1999, Vol.38 (5), p.597-601 |
| issn | 0284-186X 1651-226X |
| language | eng |
| recordid | cdi_swepub_primary_oai_swepub_ki_se_604748 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Taylor & Francis Journals Complete |
| subjects | Adult Aged Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Breast Neoplasms - drug therapy Breast Neoplasms - pathology Cell Division Chemotherapy Cyclophosphamide - administration & dosage Disease-Free Survival Epirubicin - administration & dosage Female Fluorouracil - administration & dosage Humans Ki-67 Antigen - analysis Medical sciences Middle Aged Neoadjuvant Therapy Neoplasm Recurrence, Local Patient Selection Pharmacology. Drug treatments Predictive Value of Tests Prognosis Treatment Outcome |
| title | Proliferating Fraction During Neoadjuvant Chemotherapy of Primary Breast Cancer in Relation to Objective Local Response and Relapse-free Survival |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T17%3A34%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Proliferating%20Fraction%20During%20Neoadjuvant%20Chemotherapy%20of%20Primary%20Breast%20Cancer%20in%20Relation%20to%20Objective%20Local%20Response%20and%20Relapse-free%20Survival&rft.jtitle=Acta%20oncologica&rft.au=BILLGREN,%20A.-M&rft.date=1999&rft.volume=38&rft.issue=5&rft.spage=597&rft.epage=601&rft.pages=597-601&rft.issn=0284-186X&rft.eissn=1651-226X&rft.coden=ACTOEL&rft_id=info:doi/10.1080/028418699431186&rft_dat=%3Cpubmed_swepu%3E10427948%3C/pubmed_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/10427948&rfr_iscdi=true |